blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP0621480

EP0621480 - Monitoring of lung cancer patients by measurement of NCA 50/90 in blood [Right-click to bookmark this link]
Former [1994/43]Diagnosis and monitoring of lung cancer patients by measurement of NCA 50/90 in blood
[1999/37]
StatusNo opposition filed within time limit
Status updated on  01.06.2001
Database last updated on 31.08.2024
Most recent event   Tooltip06.08.2004Lapse of the patent in a contracting state
New state(s): LU		published on 22.09.2004  [2004/39]
Applicant(s)For all designated states
BAYER CORPORATION
100 Bayer Road
Pittsburgh, PA 15205-9741 / US
[N/P]
Former [2000/31]For all designated states
Bayer Corporation
100 Bayer Road
Pittsburgh, PA 15205-9741 / US
Former [1997/40]For all designated states
Bayer Corporation
100 Bayer Road
Pittsburgh, PA 15205 / US
Former [1995/29]For all designated states
Bayer Corporation
One Mellon Center 500 Grant Street
Pittsburgh, PA 15219-2502 / US
Former [1995/28]For all designated states
MILES INC.
One Mellon Center 500 Grant St.
Pittsburgh, PA 15219-2502 / US
Former [1995/26]For all designated states
Bayer Corporation
One Mellon Center 500 Grant Street
Pittsburgh, PA 15219-2502 / US
Former [1994/43]For all designated states
MILES INC.
One Mellon Center 500 Grant St.
Pittsburgh, PA 15219-2502 / US
Inventor(s)01 / Allard, William Jeffrey
93, Stowe Drive
Poughquag, New York 12570 / US
02 / Yeung, Kwok K.
15 Taporneck Court
Ridgefield, Connecticut 06877 / US
[1994/43]
Representative(s)Burkert, Frank, et al
Bayer Schering Pharma Aktiengesellschaft
Law and Patents
Patents and Licensing
Building Q 18
51368 Leverkusen / DE
[N/P]
Former [2000/04]Burkert, Frank, et al
Bayer AG, Konzernbereich RP Patente und Lizenzen
51368 Leverkusen / DE
Former [1995/26]Dänner, Klaus, et al
Bayer AG Konzernzentrale RP Patente Konzern
D-51368 Leverkusen / DE
Former [1994/43]Dänner, Klaus, Dr.
Bayer AG Konzernverwaltung RP Patente Konzern
D-51368 Leverkusen / DE
Application number, filing date94106222.621.04.1994
[1994/43]
Priority number, dateUS1993005111121.04.1993         Original published format: US 51111
US1994019397608.02.1994         Original published format: US 193976
[1994/43]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP0621480
Date:26.10.1994
Language:EN
[1994/43]
Type: A3 Search report 
No.:EP0621480
Date:06.09.1995
Language:EN
[1995/36]
Type: B1 Patent specification 
No.:EP0621480
Date:02.08.2000
Language:EN
[2000/31]
Search report(s)(Supplementary) European search report - dispatched on:EP25.07.1995
ClassificationIPC:G01N33/574
[1994/43]
CPC:
G01N33/57423 (EP,US)
Designated contracting statesAT,   BE,   CH,   DE,   DK,   ES,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   NL,   PT,   SE [1994/43]
TitleGerman:Überwachung von Patienten mit Lungenkrebs durch Messung von NCA 50/90 im Blut[1999/37]
English:Monitoring of lung cancer patients by measurement of NCA 50/90 in blood[1999/37]
French:Surveillance de malades de cancer du poumon par mesurage de NCA 50/90 dans le sang[1999/37]
Former [1994/43]Diagnose und Überwachung von Patienten mit Lungenkrebs durch Messung von NCA 50/90 im Blut
Former [1994/43]Diagnosis and monitoring of lung cancer patients by measurement of NCA 50/90 in blood
Former [1994/43]Diagnostic et surveillance de malades de cancer du poumon par mesurage de NCA 50/90 dans le sang
Examination procedure24.02.1996Examination requested  [1996/17]
22.12.1998Despatch of a communication from the examining division (Time limit: M04)
22.04.1999Reply to a communication from the examining division
19.08.1999Despatch of communication of intention to grant (Approval: Yes)
03.11.1999Communication of intention to grant the patent
14.02.2000Fee for grant paid
14.02.2000Fee for publishing/printing paid
Opposition(s)03.05.2001No opposition filed within time limit [2001/29]
Fees paidRenewal fee
25.03.1996Renewal fee patent year 03
24.03.1997Renewal fee patent year 04
26.03.1998Renewal fee patent year 05
06.04.1999Renewal fee patent year 06
03.04.2000Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT02.08.2000
BE02.08.2000
CH02.08.2000
ES02.08.2000
GR02.08.2000
LI02.08.2000
NL02.08.2000
DK02.11.2000
PT02.11.2000
SE02.11.2000
LU21.04.2001
IE23.04.2001
[2004/39]
Former [2004/07]AT02.08.2000
BE02.08.2000
CH02.08.2000
ES02.08.2000
GR02.08.2000
LI02.08.2000
NL02.08.2000
DK02.11.2000
PT02.11.2000
SE02.11.2000
IE23.04.2001
Former [2003/45]AT02.08.2000
BE02.08.2000
CH02.08.2000
ES02.08.2000
LI02.08.2000
NL02.08.2000
DK02.11.2000
PT02.11.2000
SE02.11.2000
IE23.04.2001
Former [2003/08]AT02.08.2000
BE02.08.2000
CH02.08.2000
ES02.08.2000
LI02.08.2000
NL02.08.2000
PT02.11.2000
SE02.11.2000
IE23.04.2001
Former [2002/48]AT02.08.2000
BE02.08.2000
CH02.08.2000
ES02.08.2000
LI02.08.2000
PT02.11.2000
SE02.11.2000
IE23.04.2001
Former [2002/26]AT02.08.2000
BE02.08.2000
CH02.08.2000
ES02.08.2000
LI02.08.2000
PT02.11.2000
SE02.11.2000
Former [2002/02]AT02.08.2000
BE02.08.2000
CH02.08.2000
LI02.08.2000
PT02.11.2000
SE02.11.2000
Former [2001/27]AT02.08.2000
BE02.08.2000
PT02.11.2000
SE02.11.2000
Former [2001/22]AT02.08.2000
BE02.08.2000
PT02.11.2000
Former [2001/18]AT02.08.2000
PT02.11.2000
Former [2001/17]AT02.08.2000
Documents cited:Search[A]JPH01120289  ;
 [A]EP0446602  (MOLECULAR DIAGNOSTICS INC [US]) [A] 1,2,9 * table 1 *;
 [DPA]EP0549974  (MILES INC [US]) [DPA] 1-10 * column W *;
 [DX]  - RECK ET AL., "Determination of CEA and different NCAs ....", TUMOR BIOLOGY, BASEL, vol. 13, pages 110 - 111 [DX] 1-3,7,8 * the whole document *
 [DA]  - YEUNG ET AL., "Charcterization of a monoclonal antibody specific for NCA50/90", TUMOR BIOLOGY, BASEL, vol. 13, page 119 [DA] 1,2,7-9 * the whole document *
 [A]  - DATABASE WPI, 1, Derwent World Patents Index, vol. 89, no. 25, Database accession no. 89-182356, & JPH01120289 A 19890512 (SUNTORY LTD) [A] * abstract *
 [PX]  - ALLARD ET AL., "Nonspecific cross-reacting antigen ....", CANCER RESEARCH, CHICAGO ILL, (19940301), vol. 54, pages 1227 - 1234, XP000196357 [PX] 1-10 * the whole document *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.